The current efforts on drug development have been mostly focused on targeting a small fraction of the human proteome with good pharmacological tractability (e.g., kinases). It has been estimated, however, that approximately 90% of human proteins (e.g., transcription factors, adaptors and intrinsically disordered proteins) have not been effectively targeted by small-molecule drugs, because, for example, they lack traditionally defined binding pockets. Students will be involved in the analyses of novel covalent protein modifications and the development of chemoproteomic technologies that potentially will revolutionize the principle of drug development by pushing the boundaries of the druggable proteome. Furthermore, students will have a chance to work with experts on projects related to AI and computational biology to rapidly identify novel druggable targets in the human proteome.